International Stem Cell Corp. (ISCO.OB) Teams with Cytograft to Develop a Method to Cultivate Living Human Grafts
Biotechnology company International Stem Cell Corp. (OTCBB: ISCO) is recognized as the first company to successfully create a human “parthenogenetic” stem cell from unfertilized human eggs. The company today announced it is working in collaboration with tissue engineers at Cytograft Tissue Engineering to make headway in human vascular grafts. Scientists at International Stem Cells’ subsidiary, Lifeline Cell Technology, will work with Cytrograft to develop and produce a customized cell culture to cultivate living human grafts, which is anticipated to be an advancement over previously used materials. Todd McAllister Ph.D., CEO of Cytograft, "The team at Lifeline Cell Technologies is uniquely…